Login / Signup

Risk-benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: a prospective cohort study.

C Seree-AphinanPoonkiat SuchonwanitPloysyne RattanakaemakornC PomsoongY RatanapokasatitC SetthaudomT SuangtamaiKumutnart Chanprapaphnull null
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • coronavirus disease
  • breast cancer risk